About Blueprint Medicines (NASDAQ:BPMC)
Blueprint Medicines Corporation is a biopharmaceutical company. The Company focuses on patients with genomically defined diseases driven by abnormal kinase activation. It focuses on crafting drug candidates that provide clinical responses to patients without adequate treatment options. It has developed a small molecule drug pipeline in cancer and a genetic disease. Its drug candidate, BLU-285, targets KIT, including Exon 17 mutations, and targets PDGFRa, including the D842V mutation. These mutations activate receptor tyrosine kinases that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors (GIST), and systemic mastocytosis (SM). Its drug candidate BLU-554 targets FGFR4, a kinase that is activated in a defined subset of patients with hepatocellular carcinoma (HCC), the common type of liver cancer. It is engaged in developing BLU-667, a drug candidate that targets RET, a receptor tyrosine kinase that is activated by mutations or translocations.
Industry, Sector and Symbol
Trailing P/E Ratio-25.0976218570132
Forward P/E Ratio-20.29
Sales & Book Value
Annual Sales$21.43 million
Price / Sales200.66
Price / CashN/A
Book Value$14.55 per share
Price / Book6.76
Return on Equity-38.79%
Return on Assets-32.32%
Blueprint Medicines (NASDAQ:BPMC) Frequently Asked Questions
What is Blueprint Medicines' stock symbol?
Blueprint Medicines trades on the NASDAQ under the ticker symbol "BPMC."
How were Blueprint Medicines' earnings last quarter?
Blueprint Medicines Corp (NASDAQ:BPMC) issued its quarterly earnings results on Wednesday, February, 21st. The biotechnology company reported ($1.23) earnings per share for the quarter, missing the consensus estimate of ($1.07) by $0.16. The biotechnology company earned $1.63 million during the quarter, compared to analysts' expectations of $5.28 million. Blueprint Medicines had a negative return on equity of 38.79% and a negative net margin of 691.30%. The company's quarterly revenue was down 78.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.75) earnings per share. View Blueprint Medicines' Earnings History.
When will Blueprint Medicines make its next earnings announcement?
Where is Blueprint Medicines' stock going? Where will Blueprint Medicines' stock price be in 2018?
10 brokers have issued 1 year price targets for Blueprint Medicines' shares. Their forecasts range from $56.00 to $99.00. On average, they anticipate Blueprint Medicines' stock price to reach $83.78 in the next year. View Analyst Ratings for Blueprint Medicines.
What are Wall Street analysts saying about Blueprint Medicines stock?
Here are some recent quotes from research analysts about Blueprint Medicines stock:
- 1. According to Zacks Investment Research, "Blueprint Medicines Corp is an oncology company which is engaged in developing kinase inhibitors for genomically defined cancer subsets. Blueprint Medicines Corp is based in Cambridge, MA. " (2/23/2018)
- 2. Cowen Inc analysts commented, "We maintain our BUY rating following the Q3/17 results. Histogenics reported zero revenue and a diluted net loss of $5.1M, compared to CG/ consensus of $6.5M/$6.3M net loss, and LPS of $(0.23), compared with CG/consensus estimate of $(0.29)/$(0.28). As anticipated, the Q3 call was largely uneventful as Histogenics awaits one-year data from the NeoCart Phase 3 clinical trial. Management noted that 65% of patients are now at the one-year mark and reiterated their expectation for one-year data to be announced in Q3/18." (11/10/2017)
Who are some of Blueprint Medicines' key competitors?
Some companies that are related to Blueprint Medicines include Seattle Genetics (SGEN), SAGE Therapeutics (SAGE), Neurocrine Biosciences (NBIX), Exelixis (EXEL), Stada Arzneimittel (STDAF), Ionis Pharmaceuticals (IONS), EXACT Sciences (EXAS), Valeant Pharmaceuticals Intl (VRX), BIO-TECHNE (TECH), Dr. Reddy's Laboratories (RDY), Catalent (CTLT), Sarepta Therapeutics (SRPT), Galapagos (GLPG), Swedish Orphan Bio (SWTUY), AveXis (AVXS), United Therapeutics (UTHR), Orion (ORINY) and Integra Lifesciences (IART).
Who are Blueprint Medicines' key executives?
Blueprint Medicines' management team includes the folowing people:
- Daniel S. Lynch, Chairman of the Board (Age 59)
- Jeffrey W. Albers, President, Chief Executive Officer, Director (Age 46)
- Tracey L. Mccain, executive vice president and chief legal (Age 49)
- Marion Dorsch Ph.D., Chief Scientific Officer (Age 52)
- Michael Landsittel, Vice President, Finance (Age 45)
- Anthony L. Boral M.D. Ph.D., Chief Medical Officer (Age 54)
- Kathryn Haviland, Chief Business Officer (Age 41)
- Alexis Borisy, Director (Age 45)
- Lonnel Coats, Independent Director (Age 52)
- George D. Demetri, Independent Director (Age 60)
When did Blueprint Medicines IPO?
(BPMC) raised $115 million in an IPO on Thursday, April 30th 2015. The company issued 7,200,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Cowen and Company acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.
Has Blueprint Medicines been receiving favorable news coverage?
Media headlines about BPMC stock have been trending somewhat negative on Thursday, Accern Sentiment reports. The research group identifies negative and positive news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Blueprint Medicines earned a media sentiment score of -0.11 on Accern's scale. They also gave media headlines about the biotechnology company an impact score of 44.99 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the near future.
Who are Blueprint Medicines' major shareholders?
Blueprint Medicines' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.19%), OppenheimerFunds Inc. (3.81%), Perceptive Advisors LLC (2.66%), TimesSquare Capital Management LLC (2.58%), Alliancebernstein L.P. (2.03%) and BVF Inc. IL (1.79%). Company insiders that own Blueprint Medicines stock include Anthony L Boral, Christoph Lengauer, Daniel Lynch, George Demetri, Jeffrey W Albers, Kate Haviland, Kevin P Starr, Marion Dorsch, Mark J Levin, Nicholas Lydon and Rock Ventures Ii LP Third. View Institutional Ownership Trends for Blueprint Medicines.
Which major investors are selling Blueprint Medicines stock?
BPMC stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, Alliancebernstein L.P., Two Sigma Investments LP, Jennison Associates LLC, Foundry Partners LLC, First Trust Advisors LP, Wells Fargo & Company MN and Metropolitan Life Insurance Co. NY. Company insiders that have sold Blueprint Medicines company stock in the last year include Anthony L Boral, Daniel Lynch, George Demetri, Jeffrey W Albers, Kate Haviland, Marion Dorsch and Nicholas Lydon. View Insider Buying and Selling for Blueprint Medicines.
Which major investors are buying Blueprint Medicines stock?
BPMC stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, TimesSquare Capital Management LLC, OppenheimerFunds Inc., Artal Group S.A., BlackRock Inc., Driehaus Capital Management LLC, Monashee Investment Management LLC and California Public Employees Retirement System. View Insider Buying and Selling for Blueprint Medicines.
How do I buy shares of Blueprint Medicines?
Shares of BPMC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Blueprint Medicines' stock price today?
One share of BPMC stock can currently be purchased for approximately $98.40.
How big of a company is Blueprint Medicines?
Blueprint Medicines has a market capitalization of $4.48 billion and generates $21.43 million in revenue each year. The biotechnology company earns $-148,110,000.00 in net income (profit) each year or ($3.89) on an earnings per share basis. Blueprint Medicines employs 149 workers across the globe.
How can I contact Blueprint Medicines?
Blueprint Medicines' mailing address is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-374-7580 or via email at [email protected]
MarketBeat Community Rating for Blueprint Medicines (BPMC)MarketBeat's community ratings are surveys of what our community members think about Blueprint Medicines and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Blueprint Medicines (NASDAQ:BPMC) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||3.00||3.00||3.00||3.00|
|Ratings Breakdown: ||0 Sell Rating(s)|
0 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$83.78||$83.78||$83.78||$55.88|
|Price Target Upside: ||14.86% downside||16.58% upside||16.58% upside||12.49% downside|
Blueprint Medicines (NASDAQ:BPMC) Consensus Price Target History
Blueprint Medicines (NASDAQ:BPMC) Analyst Ratings History
(Data available from 3/22/2016 forward)
Blueprint Medicines (NASDAQ:BPMC) Earnings History and Estimates Chart
Blueprint Medicines (NASDAQ BPMC) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|2/21/2018||Q4 2017||($1.07)||($1.23)||$5.28 million||$1.63 million||View||N/A|
|10/31/2017||Q3 2017||($0.90)||($0.96)||$5.35 million||$8.07 million||View||N/A|
|8/2/2017||Q2 2017||($0.75)||($0.86)||$5.96 million||$5.89 million||View||Listen|
|5/3/2017||Q1 2017||($0.73)||($0.84)||$6.02 million||$5.84 million||View||Listen|
|3/9/2017||Q4 2016||($0.76)||($0.75)||$6.31 million||$7.69 million||View||Listen|
|11/10/2016||Q316||($0.77)||($0.62)||$6.06 million||$6.16 million||View||Listen|
|8/9/2016||Q216||($0.73)||($0.70)||$4.41 million||$7.07 million||View||Listen|
|5/10/2016||Q116||($0.70)||($0.57)||$3.24 million||$6.90 million||View||Listen|
|3/11/2016||Q415||($0.53)||($0.58)||$2.85 million||$4.64 million||View||N/A|
|11/9/2015||Q3||($0.54)||($0.47)||$1.83 million||$3.43 million||View||N/A|
|8/10/2015||Q2 2015||($0.44)||($0.81)||$0.94 million||$2.69 million||View||N/A|
|6/11/2015||Q1 2015||($6.20)||($8.23)||$0.94 million||$0.65 million||View||N/A|
Blueprint Medicines (NASDAQ:BPMC) Earnings Estimates
2018 EPS Consensus Estimate: ($4.48)
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Blueprint Medicines (NASDAQ:BPMC)
No dividend announcements for this company have been tracked by MarketBeat.com
Blueprint Medicines (NASDAQ BPMC) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 3.40%
Institutional Ownership Percentage: 97.79%
Blueprint Medicines (NASDAQ BPMC) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|3/19/2018||George Demetri||Director||Sell||5,492||$100.09||$549,694.28||10,231|| |
|3/15/2018||Marion Dorsch||Insider||Sell||2,300||$100.07||$230,161.00||2,300|| |
|3/2/2018||Jeffrey W Albers||CEO||Sell||20,000||$92.57||$1,851,400.00||20,000|| |
|2/28/2018||Nicholas Lydon||Director||Sell||25,000||$87.89||$2,197,250.00||193,131|| |
|2/14/2018||Daniel Lynch||Director||Sell||12,500||$80.42||$1,005,250.00||174,342|| |
|2/12/2018||Daniel Lynch||Director||Sell||17,500||$74.84||$1,309,700.00||202,812|| |
|2/12/2018||Kate Haviland||Insider||Sell||6,775||$74.93||$507,650.75||12,649|| |
|11/21/2017||Marion Dorsch||Insider||Sell||18,334||$65.45||$1,199,960.30||18,334|| |
|11/15/2017||Daniel Lynch||Director||Sell||5,000||$63.38||$316,900.00|| |
|11/6/2017||Anthony L Boral||Insider||Sell||5,000||$70.40||$352,000.00|| |
|11/6/2017||Jeffrey W Albers||CEO||Sell||30,000||$70.31||$2,109,300.00|| |
|10/5/2017||Kate Haviland||Insider||Sell||5,449||$66.44||$362,031.56|| |
|9/18/2017||Daniel Lynch||Director||Sell||2,500||$60.00||$150,000.00||209,342|| |
|9/18/2017||Kate Haviland||Insider||Sell||6,356||$60.03||$381,550.68||6,356|| |
|8/9/2017||Anthony L Boral||Insider||Sell||5,000||$48.60||$243,000.00||5,000|| |
|8/8/2017||Jeffrey W Albers||CEO||Sell||30,000||$49.62||$1,488,600.00||18,272|| |
|8/7/2017||Jeffrey W Albers||CEO||Sell||20,000||$49.08||$981,600.00||18,272|| |
|7/5/2017||Daniel Lynch||Director||Sell||7,500||$55.06||$412,950.00||211,842|| |
|7/5/2017||Kate Haviland||Insider||Sell||7,265||$54.66||$397,104.90||7,265|| |
|6/28/2017||Daniel Lynch||Director||Sell||32,500||$50.28||$1,634,100.00|| |
|6/28/2017||Jeffrey W Albers||CEO||Sell||20,000||$50.47||$1,009,400.00||47,920|| |
|6/28/2017||Kate Haviland||Insider||Sell||6,357||$50.00||$317,850.00||6,357|| |
|3/16/2017||Mark J Levin||Major Shareholder||Sell||30,000||$40.88||$1,226,400.00||116,444|| |
|2/7/2017||Rock Ventures Ii L.P. Third||Major Shareholder||Sell||1,000,000||$35.28||$35,280,000.00|| |
|12/19/2016||Kevin P. Starr||Major Shareholder||Sell||106,489||$28.19||$3,001,924.91|| |
|12/1/2016||Daniel Lynch||Director||Sell||200||$30.02||$6,004.00||255,694|| |
|10/13/2016||Daniel Lynch||Director||Sell||21,800||$30.02||$654,436.00|| |
|8/8/2016||Jeffrey W Albers||CEO||Sell||17,000||$22.86||$388,620.00||76,494|| |
|6/3/2016||Jeffrey W Albers||CEO||Sell||17,000||$20.03||$340,510.00||92,486|| |
|4/13/2016||Christoph Lengauer||Insider||Sell||15,872||$20.01||$317,598.72||56,657|| |
|4/12/2016||Christoph Lengauer||Insider||Sell||18,853||$20.14||$379,699.42||82,845|| |
|4/6/2016||Jeffrey W Albers||CEO||Sell||17,000||$20.42||$347,140.00||109,486|| |
|12/17/2015||Christoph Lengauer||insider||Sell||31,119||$25.05||$779,530.95||72,215|| |
|11/27/2015||Fmr Llc||Insider||Sell||287,415||$21.48||$6,173,674.20|| |
|11/24/2015||Fmr Llc||Insider||Sell||161,271||$20.14||$3,247,997.94|| |
|11/23/2015||Fmr Llc||Insider||Sell||189,572||$20.15||$3,819,875.80|| |
|11/19/2015||Fmr Llc||Insider||Sell||237,218||$19.76||$4,687,427.68|| |
|11/17/2015||Fmr Llc||Insider||Sell||27,490||$20.60||$566,294.00|| |
|11/3/2015||Christoph Lengauer||insider||Sell||84,998||$21.05||$1,789,207.90||103,334|| |
Blueprint Medicines (NASDAQ BPMC) News Headlines
|George Demetri Sells 5,492 Shares of Blueprint Medicines Corp (BPMC) Stock|
www.americanbankingnews.com - March 21 at 7:14 PM
|Insider Selling: Blueprint Medicines Corp (BPMC) Insider Sells 2,300 Shares of Stock|
www.americanbankingnews.com - March 19 at 7:46 PM
|Blueprint Medicines to Present Proof-of-Concept Data from Ongoing Phase 1 Clinical Trial of BLU-667 in Patients with RET-Altered Solid Tumors in a Clinical Trials Plenary Session at AACR Annual Meeting 2018|
finance.yahoo.com - March 14 at 5:44 PM
|Blueprint Medicines (BPMC) Stock Rating Upgraded by BidaskClub|
www.americanbankingnews.com - March 10 at 4:33 PM
|Zacks: Brokerages Expect Blueprint Medicines Corp (BPMC) Will Post Quarterly Sales of $3.18 Million|
www.americanbankingnews.com - March 8 at 4:42 AM
|Blueprint Medicines Corp (BPMC) CEO Jeffrey W. Albers Sells 20,000 Shares|
www.americanbankingnews.com - March 6 at 6:14 PM
|Zacks: Analysts Expect Blueprint Medicines Corp (BPMC) to Post -$1.09 EPS|
www.americanbankingnews.com - March 6 at 3:20 PM
|Blueprint Medicines to Present at Cowen and Company 38th Annual Health Care Conference|
finance.yahoo.com - March 6 at 9:17 AM
|Blueprint Medicines Corp (BPMC) Receives Consensus Recommendation of "Buy" from Analysts|
www.americanbankingnews.com - March 3 at 12:16 PM
|Blueprint Medicines Corp (BPMC) Shares Bought by State of Wisconsin Investment Board|
www.americanbankingnews.com - March 3 at 8:46 AM
|Sei Investments Co. Has $5.62 Million Holdings in Blueprint Medicines Corp (BPMC)|
www.americanbankingnews.com - March 3 at 8:00 AM
|Blueprint Medicines Corp (BPMC) Shares Bought by Swiss National Bank|
www.americanbankingnews.com - March 2 at 7:32 PM
|Blueprint Medicines Corp (BPMC) Director Sells $2,197,250.00 in Stock|
www.americanbankingnews.com - March 2 at 6:20 PM
|27,065 Shares in Blueprint Medicines Corp (BPMC) Acquired by EAM Investors LLC|
www.americanbankingnews.com - March 2 at 1:32 PM
|Hudson Bay Capital Management LP Invests $2.26 Million in Blueprint Medicines Corp (BPMC) Stock|
www.americanbankingnews.com - March 2 at 12:48 PM
|Spark Investment Management LLC Purchases 10,400 Shares of Blueprint Medicines Corp (BPMC)|
www.americanbankingnews.com - February 27 at 4:34 PM
|Blueprint Medicines Corp (BPMC) Stake Increased by Schwab Charles Investment Management Inc.|
www.americanbankingnews.com - February 27 at 5:50 AM
|Blueprint Medicines Corp Forecasted to Post FY2022 Earnings of $0.09 Per Share (BPMC)|
www.americanbankingnews.com - February 26 at 10:14 AM
|Blueprint Medicines Corp (BPMC) to Post Q1 2018 Earnings of ($1.13) Per Share, Jefferies Group Forecasts|
www.americanbankingnews.com - February 26 at 3:16 AM
|Blueprint Medicines (BPMC) Downgraded to "Sell" at Zacks Investment Research|
www.americanbankingnews.com - February 23 at 7:24 PM
|Brokers Offer Predictions for Blueprint Medicines Corp's FY2022 Earnings (BPMC)|
www.americanbankingnews.com - February 23 at 5:28 PM
|Blueprint Medicines Target of Unusually Large Options Trading (BPMC)|
www.americanbankingnews.com - February 23 at 8:26 AM
|Blueprint Medicines' (BPMC) Buy Rating Reiterated at Cowen|
www.americanbankingnews.com - February 21 at 8:16 PM
|Was Blueprint Medicines Corporation’s (NASDAQ:BPMC) Earnings Decline A Part Of Broader Industry Downturn?|
finance.yahoo.com - February 21 at 4:42 PM
|Blueprint Medicines (BPMC) Posts Quarterly Earnings Results, Misses Expectations By $0.16 EPS|
www.americanbankingnews.com - February 21 at 9:44 AM
|Blueprint Medicines Corp. to Host Earnings Call|
finance.yahoo.com - February 21 at 9:31 AM
| Brokerages Expect Blueprint Medicines Corp (BPMC) Will Announce Quarterly Sales of $5.09 Million|
www.americanbankingnews.com - February 19 at 1:48 AM
|Zacks: Analysts Anticipate Blueprint Medicines Corp (BPMC) Will Announce Earnings of -$1.07 Per Share|
www.americanbankingnews.com - February 17 at 11:16 PM
|Daniel Lynch Sells 12,500 Shares of Blueprint Medicines Corp (BPMC) Stock|
www.americanbankingnews.com - February 16 at 9:26 PM
|Blueprint Medicines (BPMC) Set to Announce Quarterly Earnings on Wednesday|
www.americanbankingnews.com - February 15 at 8:14 PM
|Insider Selling: Blueprint Medicines Corp (BPMC) Insider Sells 6,775 Shares of Stock|
www.americanbankingnews.com - February 14 at 6:21 PM
|Daniel Lynch Sells 17,500 Shares of Blueprint Medicines Corp (BPMC) Stock|
www.americanbankingnews.com - February 14 at 6:19 PM
|Blueprint Medicines to Report Fourth Quarter and Full Year 2017 Financial Results on Wednesday, February 21, 2018|
finance.yahoo.com - February 14 at 9:10 AM
|Head to Head Contrast: Blueprint Medicines (BPMC) vs. Crispr Therapeutics (CRSP)|
www.americanbankingnews.com - February 11 at 11:12 AM
|Analyzing Blueprint Medicines (BPMC) and Iqvia (IQV)|
www.americanbankingnews.com - February 8 at 5:10 AM
|Analyzing Blueprint Medicines (BPMC) and Concert Pharmaceuticals (CNCE)|
www.americanbankingnews.com - February 7 at 9:52 AM
|Blueprint Medicines Corp (BPMC) Given Consensus Rating of "Buy" by Analysts|
www.americanbankingnews.com - February 6 at 9:14 AM
|Celyad (CYAD) & Blueprint Medicines (BPMC) Head-To-Head Analysis|
www.americanbankingnews.com - February 2 at 7:08 PM
| Analysts Anticipate Blueprint Medicines Corp (BPMC) Will Post Quarterly Sales of $5.09 Million|
www.americanbankingnews.com - February 2 at 4:26 AM
|Blueprint Medicines (BPMC) Rating Increased to Buy at Zacks Investment Research|
www.americanbankingnews.com - January 15 at 7:28 PM
|Zacks: Brokerages Expect Blueprint Medicines Corp (BPMC) Will Post Earnings of -$1.07 Per Share|
www.americanbankingnews.com - January 15 at 1:10 AM
|Blueprint Medicines Corp (BPMC) Given Consensus Rating of "Buy" by Brokerages|
www.americanbankingnews.com - January 12 at 8:02 AM
|Zacks Investment Research Lowers Blueprint Medicines (BPMC) to Hold|
www.americanbankingnews.com - January 11 at 6:20 PM
|Blueprint Medicines (BPMC) Upgraded to "Buy" at Zacks Investment Research|
www.americanbankingnews.com - January 8 at 7:52 PM
|Head to Head Analysis: Blueprint Medicines (BPMC) and SAGE Therapeutics (SAGE)|
www.americanbankingnews.com - January 6 at 1:36 PM
|Zacks: Analysts Anticipate Blueprint Medicines Corporation (BPMC) Will Post Quarterly Sales of $5.09 Million|
www.americanbankingnews.com - December 31 at 10:28 AM
|Zacks: Analysts Expect Blueprint Medicines Corporation (BPMC) to Post -$1.07 Earnings Per Share|
www.americanbankingnews.com - December 29 at 5:26 AM
|Reviewing Blueprint Medicines (BPMC) and Its Rivals|
www.americanbankingnews.com - December 28 at 1:13 PM
|Blueprint Medicines (BPMC) and Its Competitors Head to Head Review|
www.americanbankingnews.com - December 23 at 11:18 PM
|Reviewing Blueprint Medicines (BPMC) & Its Peers|
www.americanbankingnews.com - December 23 at 1:12 PM
Blueprint Medicines (NASDAQ:BPMC) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Blueprint Medicines (NASDAQ:BPMC) Income Statement, Balance Sheet and Cash Flow Statement
Blueprint Medicines (NASDAQ BPMC) Stock Chart for Thursday, March, 22, 2018